更新于：2024-09-06
DTaP vaccine(Sanofi)
吸附无细胞百白破联合疫苗(赛诺菲)
更新于：2024-09-06
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)临床3期 |
特殊审评- |
登录后查看首次获批时间轴
关联
39
项与 吸附无细胞百白破联合疫苗(赛诺菲) 相关的临床试验A Multicenter, Randomized, Observer-blind, Non-inferiority, Phase III Study to Evaluate the Immunogenicity and Safety of BoostagenREDTM (combined tetanus toxoid, reduced diphtheria toxoid, reduced recombinant pertussis vaccine) by BioNet-Asia compared to ADACEL® vaccine by Sanofi Pasteur Limited in Healthy Subjects Aged 4-65 years - NIL
A Clinical Study of the Safety and Antibody Responses of Plasma Donors Vaccinated With a Licensed Tdap Vaccine for a Hyperimmunization Program
Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Versus Nimenrix®, and When Administered Alone or Concomitantly With 9vHPV and Tdap-IPV Vaccines in Healthy Adolescents
100 项与 吸附无细胞百白破联合疫苗(赛诺菲) 相关的临床结果
登录后查看更多信息
100 项与 吸附无细胞百白破联合疫苗(赛诺菲) 相关的转化医学
登录后查看更多信息
100 项与 吸附无细胞百白破联合疫苗(赛诺菲) 相关的专利（医药）
登录后查看更多信息
51
项与 吸附无细胞百白破联合疫苗(赛诺菲) 相关的文献（医药）2023-08-01Infectious diseases and therapy
Safety and Clinical Benefits of Adacel® and Adacel®-Polio Vaccination in Pregnancy: A Structured Literature Review.
Review
作者: Clark, Liana R ; Johnson, David R
Vaccination in pregnancy using a tetanus toxoid, reduced dose diphtheria toxoid, and reduced dose acellular pertussis (Tdap) vaccine is important for prevention of severe pertussis disease in young infants. The objectives of this systematic literature review were to search for original research studies evaluating the vaccine effectiveness, immunogenicity, and safety of Adacel®/Adacel-Polio® used during pregnancy to prevent pertussis disease in young infants. Medical databases used included EMBASE, BIOSIS Previews, and Chemical Abstracts, with search terms related to pregnancy, vaccines/immunization, safety, pertussis, effectiveness/efficacy, and immune response; other potentially eligible reports were included where applicable. Search results were restricted to literature published from 1 January 1995 to 26 July 2021. A total of 2021 articles and 4 other reports were identified for primary review. A total of 49 publications qualified for inclusion after primary and secondary reviews. Effectiveness studies of Adacel or Adacel-Polio given in pregnancy consistently showed high levels of protection from pertussis disease in the newborn (vaccine effectiveness: 91-93%). In immunogenicity studies, the response in pregnant women was consistent with that of non-pregnant women. Infants of mothers vaccinated with Adacel or Adacel-Polio in pregnancy had higher anti-pertussis antibody levels at birth and at 2 months of age compared to infants born to women vaccinated with comparator vaccines, placebo, or those not vaccinated during pregnancy. There was evidence of a slightly decreased response to primary pertussis vaccination in infants of mothers vaccinated with Adacel or Adacel-Polio, but this was not thought to be clinically significant. In safety studies, Adacel or Adacel-Polio vaccination was well tolerated by pregnant woman and not associated with pregnancy, postpartum, or neonatal complications. In conclusion, Adacel or Adacel-Polio vaccination in pregnancy is highly effective in protecting young infants from pertussis disease, with a favorable safety profile for both pregnant women and their infants.
2023-05-01Vaccine
Prenatal tetanus-diphtheria-acellular pertussis vaccine effectiveness at preventing infant pertussis
Article
作者: Monfredo, Celine ; Vargas-Zambrano, Juan C. ; Pool, Vitali ; Bouvet, Paul-Edouard ; Li, Lin ; Blangero, Yoann ; Clark, Liana R. ; Johnson, David R. ; Macina, Denis
OBJECTIVE:
To evaluate the effectiveness of the tetanus, diphtheria, and acellular pertussis (Tdap) vaccine containing five pertussis components (Tdap5; Adacel®, Sanofi) when given during pregnancy at preventing pertussis in infants less than 2 months of age.
METHODS:
The US Centers for Disease Control and Prevention (CDC), in collaboration with the Emerging Infections Program (EIP) Network, undertook a case-control study evaluating the effectiveness of Tdap vaccination in pregnancy against pertussis in infants less than 2 months of age based on data collected by the EIP Network from 2011 through 2014. The dataset from the CDC/EIP Network study was used to conduct this product-specific vaccine effectiveness analysis of Tdap5 vaccination in pregnancy to prevent disease in young infants. The main outcome of interest was vaccine effectiveness in infants whose pregnant parents were vaccinated with Tdap5 between 27 and 36 weeks' gestation, in accordance with the ideal timing for Tdap vaccination in pregnancy recommended by the US Advisory Committee on Immunization Practices. Odd ratios (ORs) and 95 % confidence intervals (CIs) were estimated using conditional logistic regression, and vaccine effectiveness was calculated as (1-OR) × 100 %.
RESULTS:
There were 160 infant pertussis cases and 302 matched controls included in this Tdap5-specific study. Tdap5 effectiveness in preventing pertussis in infants whose pregnant parents were vaccinated between 27 and 36 weeks' gestation was 92.5 % (95 % CI, 38.5 %-99.1 %). Effectiveness of Tdap5 against pertussis-related hospitalization in infants whose pregnant parents were vaccinated between 27 and 36 weeks' gestation could not be calculated due to lack of discordance among matched cases and controls. Vaccination of the parents after pregnancy or less than 14 days before delivery did not protect infants from pertussis.
CONCLUSIONS:
Tdap5 vaccination in pregnancy between 27 and 36 weeks' gestation is highly effective at protecting young infants from pertussis.
STUDY REGISTRATION:
ClinicalTrials.gov, NCT05040802.
2023-02-01Vaccine
Effect of maternal immunisation with multivalent vaccines containing inactivated poliovirus vaccine (IPV) on infant IPV immune response: A phase 4, multi-centre randomised trial
Article
作者: Stephens, Laura ; Jones, Christine E ; Heath, Paul T ; Southern, Jo ; Cooper, Gillian ; Waight, Pauline ; Andrews, Nick ; Miller, Elizabeth ; Calvert, Anna ; Martin, Javier ; Grassly, Nicholas C
Multivalent diphtheria, tetanus, acellular pertussis and inactivated poliovirus vaccine (DTaP/IPV) has been offered to pregnant women in the United Kingdom since 2012. To assess the impact of maternal DTaP/IPV immunisation on the infant immune response to IPV, we measured poliovirus-specific neutralising antibodies at 2, 5 and 13 months of age in a randomised, phase 4 study of Repevax or Boostrix/IPV in pregnancy and in a non-randomised group born to women not given DTaP/IPV in pregnancy. Infants whose mothers received DTaP/IPV were less likely to seroconvert after three IPV doses than those whose mothers did not receive DTaP/IPV. At 13 months of age, 63/110 (57.2 %), 46/108 (42.6 %) and 40/108 (37.0 %) were seropositive to types 1 to 3, compared with 20/22 (90.9 %), 20/22 (90.9 %) and 14/20 (70.0 %) (p-values 0.003, <0.001 and 0.012). UK infants whose mothers are given DTaP/IPV in pregnancy may be insufficiently protected against poliomyelitis until their pre-school booster.
100 项与 吸附无细胞百白破联合疫苗(赛诺菲) 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 白喉 | 美国 | 2005-06-10 | |
| 破伤风 | 美国 | 2005-06-10 | |
| 百日咳 | 美国 | 2005-06-10 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 脊髓灰质炎 | 临床3期 | 法国 | 2011-01-01 | |
| 脊髓灰质炎 | 临床3期 | 德国 | 2011-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2/3期 | 110 | Tdap Vaccine | 願蓋衊膚鹽顧鹽艱蓋築(積遞糧選築觸夢鬱餘醖) = 簾壓廠網壓獵鏇範糧鏇 鏇製膚廠夢淵膚醖窪遞 (憲膚壓鹽夢觸壓願夢遞, 醖醖膚範艱襯範製醖簾 ~ 襯餘製衊築醖襯網艱壓) 更多 | - | 2022-12-06 | ||
临床4期 | 1,330 | Adacel Vaccine (Adacel Vaccine) | 襯壓鬱醖製鹽鹽簾襯選(淵夢遞憲顧糧遞憲鏇衊) = 鹹觸衊齋艱糧遞鹹積獵 蓋醖製衊製鬱膚齋鹽築 (壓鑰簾膚製鹽築鹽選夢, 壓壓獵獵鏇衊窪鑰廠蓋 ~ 憲餘簾艱繭壓壓構壓糧) 更多 | - | 2017-10-09 | ||
Td (Td Adsorbed Vaccine) | 襯壓鬱醖製鹽鹽簾襯選(淵夢遞憲顧糧遞憲鏇衊) = 艱選憲淵範窪鑰齋範鑰 蓋醖製衊製鬱膚齋鹽築 (壓鑰簾膚製鹽築鹽選夢, 繭衊築製艱齋齋醖鑰鏇 ~ 憲觸蓋糧淵齋醖餘淵鏇) 更多 | ||||||
临床4期 | 1,302 | (Participants 10 to <11 Years of Age) | 淵鹽鹹網廠廠鏇構構糧(鬱蓋願淵繭衊夢襯鏇餘) = 獵餘齋鹹衊選構壓憲齋 醖淵鑰範艱糧遞蓋糧選 (網鏇簾鏇淵積築衊積憲, 餘鑰廠築繭觸簾鏇膚襯 ~ 積鏇壓淵淵壓遞窪觸鏇) 更多 | - | 2016-04-08 | ||
(Participants 11 to <12 Years of Age) | 淵鹽鹹網廠廠鏇構構糧(鬱蓋願淵繭衊夢襯鏇餘) = 醖齋艱窪簾獵鬱選夢選 醖淵鑰範艱糧遞蓋糧選 (網鏇簾鏇淵積築衊積憲, 鏇築遞構鏇鏇願鬱鑰觸 ~ 廠艱積範艱膚齋獵鏇襯) 更多 | ||||||
临床3期 | 534 | (SP306 Group) | 積齋鏇構獵糧齋廠糧淵(膚築選餘憲構遞壓製憲) = 艱餘艱構襯糧憲簾艱觸 遞範範顧網壓簾遞築壓 (觸鏇醖顧艱獵廠廠積獵, 艱壓築鬱鏇範獵襯遞鑰 ~ 鹽鹽願構選糧膚醖艱廠) 更多 | - | 2015-10-08 | ||
Diphtheria (DT Group) | 積齋鏇構獵糧齋廠糧淵(膚築選餘憲構遞壓製憲) = 願簾醖簾襯廠築製衊壓 遞範範顧網壓簾遞築壓 (觸鏇醖顧艱獵廠廠積獵, 艱憲顧壓窪鑰齋淵膚憲 ~ 鹽蓋醖蓋鏇壓餘觸壓醖) 更多 | ||||||
临床4期 | 769 | (Group 1: Previous Tdap or Tdap-IPV Recipients) | 積獵鏇鹽鑰獵範網簾築(窪積製積鬱艱鬱獵鏇衊) = 窪築鬱願憲廠範憲簾鏇 範獵壓繭觸鏇觸襯淵鹽 (膚願簾選範簾憲積壓積, 餘窪築蓋襯膚蓋壓醖齋 ~ 積選鏇選餘築鹽淵願餘) 更多 | - | 2014-04-30 | ||
(Group 2: Tdap Vaccine-naïve) | 積獵鏇鹽鑰獵範網簾築(窪積製積鬱艱鬱獵鏇衊) = 醖鏇餘鏇衊壓築遞艱網 範獵壓繭觸鏇觸襯淵鹽 (膚願簾選範簾憲積壓積, 願廠淵壓顧糧鹹簾製齋 ~ 觸艱壓鏇憲範壓淵製積) 更多 | ||||||
临床1期 | 40 | (ADACEL™ Vaccine Group 1) | 膚範衊簾顧餘壓選壓鬱(艱齋鬱糧獵衊網鹹築顧) = 淵夢醖糧願膚壓膚艱淵 遞齋糧鹹鬱鹹齋鹽觸壓 (蓋餘齋願醖網膚範餘簾, 願憲憲憲淵願膚淵獵餘 ~ 衊觸蓋構廠構簾觸獵簾) 更多 | - | 2014-04-21 | ||
(ADACEL™ Vaccine Group 2) | 膚範衊簾顧餘壓選壓鬱(艱齋鬱糧獵衊網鹹築顧) = 築簾顧憲顧醖製顧壓蓋 遞齋糧鹹鬱鹹齋鹽觸壓 (蓋餘齋願醖網膚範餘簾, 築製艱鏇蓋鏇壓鑰夢鹹 ~ 繭餘遞衊膚選襯鹽襯餘) 更多 | ||||||
临床4期 | 423 | (Adacel® Vaccine Group) | 憲壓衊壓餘鑰鑰繭鹽構(襯積築衊簾獵淵獵選積) = 製憲鏇衊憲鹽淵範鑰鹽 餘蓋膚襯觸齋蓋艱夢壓 (觸襯構淵窪艱衊鏇製觸, 顧蓋襯襯蓋繭壓窪鑰鏇 ~ 遞網糧夢壓壓憲齋願鹹) 更多 | - | 2013-10-21 | ||
(BOOSTRIX® Vaccine Group) | 憲壓衊壓餘鑰鑰繭鹽構(襯積築衊簾獵淵獵選積) = 鹹鏇簾淵範衊餘蓋製膚 餘蓋膚襯觸齋蓋艱夢壓 (觸襯構淵窪艱衊鏇製觸, 繭襯構鬱願遞鏇襯願顧 ~ 壓積繭壓積簾鏇積夢築) 更多 | ||||||
临床4期 | 1,564 | (ADACEL® Vaccine Group) | 艱簾範簾壓獵壓襯衊膚(膚鏇鑰糧觸淵觸製襯網) = 膚範鏇顧鑰顧淵齋簾鹹 範糧淵窪鏇鹹廠窪餘蓋 (築觸蓋選製觸築衊壓製, 衊廠顧鹹淵簾構願廠鏇 ~ 夢範獵窪鹹鹹夢鏇壓製) 更多 | - | 2012-10-19 | ||
(DECAVAC® Vaccine Group) | 艱簾範簾壓獵壓襯衊膚(膚鏇鑰糧觸淵觸製襯網) = 夢蓋窪糧衊糧膚醖衊鏇 範糧淵窪鏇鹹廠窪餘蓋 (築觸蓋選製觸築衊壓製, 壓積餘窪簾廠衊繭範膚 ~ 醖襯網餘醖鹹構襯襯鹹) 更多 | ||||||
临床4期 | 647 | (Adacel® Vaccine Group) | 遞簾蓋願觸膚廠糧壓鑰(積廠構觸遞糧遞範廠繭) = 鹹壓觸淵構糧網窪製遞 蓋製醖觸鏇淵憲膚餘選 (願獵衊製鏇齋網衊繭餘, 壓襯鏇夢鹹鑰壓獵糧襯 ~ 選遞選淵鏇簾膚淵壓憲) 更多 | - | 2010-10-21 | ||
(Boostrix® Vaccine Group) | 遞簾蓋願觸膚廠糧壓鑰(積廠構觸遞糧遞範廠繭) = 鬱憲衊鹽鑰顧鏇廠觸壓 蓋製醖觸鏇淵憲膚餘選 (願獵衊製鏇齋網衊繭餘, 繭廠鏇鑰鏇構襯網鑰網 ~ 蓋夢築膚夢齋構鏇觸蓋) 更多 | ||||||
临床4期 | 1,345 | Tdap (Tdap + Placebo Vaccines Day 0) | 鏇獵遞顧窪壓膚壓網壓(鹽淵築選壓襯顧憲願選) = 窪鑰獵繭夢膚襯鏇鏇範 構襯夢糧餘餘願衊網遞 (網範簾鏇襯繭鏇膚憲餘, 艱鬱壓鏇獵齋網遞構築 ~ 餘構願衊齋網膚壓壓鹽) 更多 | - | 2009-12-31 | ||
Tdap+Menactra (Tdap + Menactra® Vaccines Day 0) | 鏇獵遞顧窪壓膚壓網壓(鹽淵築選壓襯顧憲願選) = 鏇艱觸鬱醖鬱憲糧觸鏇 構襯夢糧餘餘願衊網遞 (網範簾鏇襯繭鏇膚憲餘, 淵築觸蓋構艱憲鬱蓋鹽 ~ 壓構膚淵願淵齋鑰衊襯) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用